Wall Street brokerages expect Intec Pharma Ltd (NASDAQ:NTEC) to announce earnings per share of ($0.22) for the current quarter, according to Zacks. Zero analysts have made estimates for Intec Pharma’s earnings. The highest EPS estimate is ($0.19) and the lowest is ($0.27). Intec Pharma reported earnings per share of ($0.28) during the same quarter last year, which would suggest a positive year over year growth rate of 21.4%. The business is expected to issue its next quarterly earnings results on Wednesday, August 21st.
On average, analysts expect that Intec Pharma will report full-year earnings of ($1.01) per share for the current financial year, with EPS estimates ranging from ($1.15) to ($0.92). For the next year, analysts expect that the business will report earnings of ($0.55) per share, with EPS estimates ranging from ($0.85) to ($0.23). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Intec Pharma.
NTEC has been the topic of several research reports. Oppenheimer lowered shares of Intec Pharma from an “outperform” rating to a “market perform” rating in a research note on Monday, July 22nd. HC Wainwright lowered shares of Intec Pharma from a “buy” rating to a “neutral” rating in a research note on Wednesday. Maxim Group lowered shares of Intec Pharma from a “buy” rating to a “hold” rating in a research note on Monday, July 22nd. Zacks Investment Research raised shares of Intec Pharma from a “sell” rating to a “hold” rating and set a $6.50 price objective on the stock in a research note on Tuesday, May 7th. Finally, LADENBURG THALM/SH SH lowered shares of Intec Pharma from a “buy” rating to a “neutral” rating in a research note on Monday, July 22nd. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $12.17.
A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in Intec Pharma during the fourth quarter valued at $67,000. Menta Capital LLC bought a new stake in Intec Pharma during the first quarter valued at $248,000. Sigma Planning Corp bought a new stake in Intec Pharma during the first quarter valued at $183,000. Private Advisors LLC bought a new stake in Intec Pharma during the first quarter valued at $225,000. Finally, Knott David M boosted its position in Intec Pharma by 2.5% during the first quarter. Knott David M now owns 290,434 shares of the biotechnology company’s stock valued at $2,129,000 after acquiring an additional 6,961 shares during the last quarter. 35.26% of the stock is currently owned by institutional investors and hedge funds.
About Intec Pharma
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
See Also: Real Estate Investment Trust (REIT) ETF
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.